Theranostics
Developing the next generation of cancer Imaging agents and TARGETED therapies
We develop new molecular imaging methods to image tumour metabolism and the downstream effect of targeted therapeutics.
These next-generation molecular imaging techniques are designed to assess the efficacy of novel and preexisting cancer therapeutics and help describe the fundamental biological mechanisms that drive treatment resistance. Harnessing the same molecular-targeted approach, we are creating new theranostics to not only ‘see’ but treat this devastating disease.
News:
Getting ready for clinical. Compact and cGMP-compliant automated synthesis of [18F]FSPG on the Trasis AllinOne™ out now!
Our latest paper Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography is out now in Nature Communications. Check it out!
🎉 Congratulations to our Group leader, Tim Witney, who has just been promoted to Professor. 🎉
New lab photo! We’re delighted to welcome new PhD student, Rosie Lewis, and Research Assistant, Huda Hammad Rattu, to the group.
our research
Our projects span the disciplines of oncology, biochemistry and the physical sciences.
People
Our multidisciplinary group is part of KCL’s School of Biomedical Engineering and Imaging Sciences.
PODCAST
The official podcast of the European Society for Molecular Imaging is co-hosted by Tim Witney and Giannis Zacharakis.